Searched for
BIOPHARMACEUTICAL SEGMENT
NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
- US stock market today: why Dow Jones crashing big while S&P 500 and Nasdaq are rising? Dow down by 200 points as oil surge, Fed jitters, and Big Tech earnings split market directionUS stock market today: Why Dow Jones Industrial Average falls while S&P 500 and Nasdaq Composite hold steady? US stock market today shows a...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Laurus Labs biotech unit raises Rs 120 crore from Eight Roads VenturesLaurus Bio has secured ₹120 crore in equity investment from Eight Roads Ventures and F-Prime Capital, with Laurus Labs co-investing ₹40 cro...
- Quadria Cap concludes Rs 475.31 crore investment in ConcordPrivate equity firm Quadria Capital has concluded a Rs 475.31 crore investment in biopharmaceutical active ingredient manufacturer Concord ...
- Dr Reddy's in licenses product from Cymbiotics; launches pain relief creamDrug maker Dr. Reddy’s Laboratories launched Supamove Cream for patients suffering from arthritis and joint pains after in licensing the pr...
- India's biotech sector to grow 20% in foreseeable futureMazumdar-Shaw said the size of the country's biotech sector had reached USD 3.5 billion in 2010 and is poised for robust growth in all segm...
- Licensing deals help Biocon post healthy Q3 nosBiocon's third quarter consolidated net profit rose 24% to 100.75 helped by inflows from licensing deals with global biggies Pfizer and Myl...
- Biocon Q2 net profit up 20 pc at Rs 89 crBuoyed by strong business from its biopharmaceutical segment, Biocon has registered a 20 pc growth in its net profit at Rs 89 crore for the...
- Recession not to hit clinical trials: CROsIndian clinical research organisations do not see any near-term impact of recession as large pharma customers such as AstraZeneca and Glaxo...
- Panacea, Intas plan biosimilar launchJoining Indian pharma majors who are targeting the $65-billion global biotech drug market.
- Biocon Q4 net up 27% to Rs 61 crBangalore-based Biocon has posted a consolidated net profit of Rs 61 crore for the fourth quarter ended March 31, 2007, up 27% from Rs 48 c...
- Fidelity to buy 12-14% stake in AvesthagenFidelity Investments is in advanced talks to buy 12-14% stake in the Bangalore-based biotech firm Avesthagen for $10-12 million.
- Reliance Life kicks off contract manufacturingMukesh Ambani’s dream project, Reliance Life Sciences (RLS) has started contract manufacturing and contract research of biopharmaceuticals ...
Load More
